Novo Nordisk
Live price unavailable. Yahoo unofficial endpoint may be throttling or the ticker may be misconfigured.
loading 1-year chart…
1-year close · Yahoo Finance · daily interval
What they do in peptide space
Novo Nordisk is the originator of the modern GLP-1 era. Liraglutide (Saxenda, daily injection), semaglutide (Ozempic for diabetes, Wegovy for weight loss, Rybelsus for oral diabetes), and the experimental CagriSema (cagrilintide + semaglutide combination) all originate here.
The SELECT cardiovascular outcomes trial (n=17,604, 20% reduction in major adverse cardiac events with semaglutide) gave Novo the first GLP-1 cardiovascular indication and reframed obesity from cosmetic to cardiometabolic. STEP-1 (semaglutide weight loss trial) and the STEP-1 extension are the canonical references for what to expect from semaglutide-based weight loss and what happens on discontinuation.
Novo is also the supplier most affected by the May 2026 FDA proposal to exclude semaglutide from the 503B bulks list — a move that, if finalized, materially reshapes the compounded-semaglutide market in favor of branded Wegovy and Ozempic. Novo's position is that compounded semaglutide is no longer needed under FDA shortage rules.
Recent mentions
Coming soon — no editorial coverage or FDA alert mentioning Novo Nordisk in our index yet. Items will surface here as the news / FDA cron pipelines ingest them.